Objectives This drug utilization evaluation aims to review current evidence on safety and efficacy of using liposomal amphotericin B (LAMB) in newborns with candidiasis, and compare it to the conventional preparation. Conventional amphotericin B deoxycholate (DAMB) is more commonly used in newborns, but dose-limiting adverse effects may compromise its efficacy. This review will examine the advantages and disadvantages of liposomal amphotericin B and define its place in current practice. Key Findings The terms 'AmBisome' or 'liposomal amphotericin B' and 'neonatal candidiasis' were entered in both PubMed and Ovid; studies included focused on safety and efficacy of liposomal amphotericin B in newborns with candidiasis, as well as studies comparing the conventional and the liposomal formulations in newborns as monotherapy. Pertinent references obtained from this search were also included. Additionally, pharmacokinetic studies were reviewed to include available data on dosing. Single case reports were not included in the review due to the limited conclusions that can be drawn from such sample sizes and quality of data. Summary Although liposomal amphotericin B may be better tolerated and as efficacious as the conventional formulation based on the published literature, the weakness of the studies available on the subject cannot be overlooked. Additional randomized controlled trials are needed to determine the true benefits of this medication.
Introduction
Neonatal candidiasis (NC) is associated with significant mortality in preterm newborns, and neurodevelopmental impairment among survivors, especially following Candida meningitis. [1, 2] Conventional amphotericin B remains the drug of choice in neonatal candidiasis in the United States due to the lack of studies available on alternative agents. Although additional formulations of amphotericin exist, this review will focus on summarizing and evaluating the available data on the use of liposomal amphotericin B (LAMB; AmBisome; Gilead Sciences, Foster City, CA, USA) in neonatal candidiasis, as an alternative option to conventional amphotericin B deoxycholate (DAMB; Fungizone; Bristol-Myers Squibb, NY, NY, USA). Alternative liposomal formulations include amphotericin B lipid complex (ABLC; Abelcet; Liposome Company, Princeton, NJ, USA) and amphotericin B colloidal dispersion (ABCD; Amphocil; Sequus Pharmaceuticals, Menlo Park, CA, USA), which vary in formulation, pharmacokinetic and pharmacodynamic parameters and should not be used interchangeably with LAMB. Although many reviews are available regarding the use of LAMB in adults, the available literature reviews currently do not focus on the use of this formulation in NC.
Background Incidence
Although the incidence of NC has declined over time due to risk factor modification and the use of fluconazole prophylaxis, NC remains one of the major causes of late-onset sepsis in newborns. [1] Specifically, it is reported to affect 4-20% of extremely low birthweight (ELBW) [<1000 g] and 1-4% of very low birthweight (VLBW) (<1500 g) infants. [1] A study looking at infants with a birthweight over 1500 g determined risk factors for NC in this population, including vaginal birth, day of life >7, the presence of central lines, broad-spectrum antibiotic use, antifungal prophylaxis and platelet count <50 000 mm 3 . Major clinical parameters associated with neonatal candidiasis included thrombocytopenia combined with broad-spectrum antibiotic use, which is similar to the major risk factors in VLBW infants. [3] Mycology In NC, Candida albicans remains the primary causative organism (55%), followed by Candida parapsilosis (35%), and less frequently Candida tropicalis, Candida glabatra and Candida krusei. [4] Non-albicans Candida species have been associated with a rising proportion of NC. [4] A recent prospective international epidemiologic study reported non-albicans species to be responsible for 52% of neonatal candidiasis infections. [4] The widespread use of fluconazole as the primary prophylactic option for NC in neonates with birthweights <1000 g, may have influenced this shift towards non-albicans Candida pathogens, rather than contributing to resistance patterns due to overexposure. [4, 5] Additionally, the inherent resistance to fluconazole of C. tropicalis, C. glabatra and C. krusei warrants special consideration when evaluating therapeutic options for NC.
A recent meta-analysis reported an associated mortality rate of 10.02% with C. parapsilosis. [6] Although the virulence of C. parapsilosis has not been well-characterized, biofilm formation is a common trait of the Candida species, including C. parapsilosis and C. albicans. [7] Both echinocandins and LAMB were reported to have increased biofilm inhibition activity when compared to DAMB and to fluconazole, which completely lacks antibiofilm efficacy. [7] This advantageous activity of LAMB was reported against C. albicans and against specific strains of C. parapsilosis. [7, 8] Additional studies are needed to determine the clinical significance of this potentially advantageous trait of LAMB.
Pharmacokinetics Conventional amphotericin B deoxycholate
Amphotericin B deoxycholate exhibits concentrationdependent fungicidal activity, has a wide spectrum of activity and is associated with rare resistance patterns present in some non-albicans Candida species, including trichosporon, scedosporium, and fusarium species, although these do not cause invasive candidiasis. [9] Amphotericin B binds to ergosterol, present in fungal cell membranes, impairing the integrity of the cell membrane, resulting in increased permeability and cell death. To a lesser extent, amphotericin B also binds to cholesterol, present in human cell membranes, resulting in adverse effects such as nephrotoxicity and hepatotoxicity. Due to poor bioavailability following oral administration, amphotericin B is generally administered intravenously and as a deoxycholate salt to improve solubility. Once in systemic circulation, the deoxycholate salt dissociates to allow for the amphotericin B molecule to bind to lipoproteins and distribute into tissues through the reticuloendothelial system. Cerebrospinal fluid (CSF) penetration is limited in adults (5-10%), but appears to be increased in newborns (40-90%) due to the increased permeability of the blood-brain barrier associated with meningeal inflammation and age-related immaturity. [10] Pharmacokinetic (PK) studies of DAMB in newborns are rare, and PK data are mostly extrapolated from adults PK studies. Baley et al. found extensive interindividual variability for half-life, clearance and volume of distribution in neonates. However, based on accumulated clinical data, DAMB use in newborns seems to be associated with a faster elimination [0.03-0.22 l/kg per h vs 0.03 l/kg per h], lower volume of distribution (0.4-3.1 l/kg vs 4 l/kg), lower serum concentrations and a longer half-life than adults, which may be due to a delayed elimination associated with the three compartment model that is usually seen in newborns. [10, 11] This faster elimination is thought to contribute to the decreased incidence of nephrotoxicity seen in newborns vs adults. Elevation in serum creatinine (SCr) and blood urea nitrogen (BUN) was seen in one-third of the infants included in this study and was associated with reduced renal elimination of DAMB in these infants. Based on adult PK studies, DAMB distributes widely into tissues and is mainly eliminated unchanged through biliary and renal excretion. [12] Liposomal amphotericin B Liposomal amphotericin B was developed in the 1980s, as an alternative agent in response to high rates of toxicities occurring from the use of DAMB. LAMB is formulated in small liposomes, and is less phagocytized by the mononuclear phagocyte system than the conventional formulation due to its small size, thus effectively escaping immediate clearance. As a result, the decreased uptake by phagocytic cells allows for an increased area under the curve (AUC). Additionally, the liposomal formulation was shown to have notably lower concentrations than DAMB in the kidneys, which may explain the difference in nephrotoxicity between these agents. [13] This is thought to be associated with the increased affinity of liposomes to fungal cell walls, effectively minimizing the interaction with host cell membranes, preventing host membrane rupture and subsequent adverse effects and providing a targeted delivery to the site of infection. Once at the site of infection, amphotericin B is released from the lipid formulation via lipases produced by the fungus or by the abundant inflammatory cells present at the infection site. [12] The change in formulation of amphotericin B is also associated with changes in the PK profile, including a delayed onset of action as well as a higher serum concentration, as compared to the conventional formulation. [14] The delayed onset of action may be related to a delayed uptake by the mononuclear phagocyte system due to a smaller sized and negatively charged molecule. [12] The ability to reach higher serum concentrations at a given dose, vs the conventional formulation, harnesses the power of the concentration-dependent killing mechanism of this medication, and may be related to an initial lower volume of distribution in adults. At steady state, the volume of distribution significantly increases, correlating with the delayed uptake by the mononuclear phagocyte system. Additionally, this formulation is associated with a slower clearance, which can lead to accumulation and contributes to the ability to reach increasing serum concentrations, which may result in increased efficacy of the medication.
Unlike DAMB, LAMB is minimally renally eliminated, which may explain the decreased incidence of nephrotoxicity associated with this formulation. As a result, it is hypothesized that the potential use of LAMB to treat urinary candidiasis is minimized due to the minimal renal excretion. The elimination pathway of LAMB is largely unknown in adults, but it does not seem to be hepatically cleared, as adult PK studies do not indicate the presence of metabolites, and known clearance pathways are only able to account for 24% of the original dose of LAMB. [15] While animal studies showed significantly higher central nervous system (CNS) tissue concentrations with LAMB when compared to DAMB, this finding has not been confirmed in neonates. [14] The lack of renal penetration and uncertainty regarding CNS penetration in humans remains the most limiting factor for the use of LAMB for NC in current practice.
Efficacy Conventional amphotericin B deoxycholate
Although geographical practice variation exists, DAMB tends to be used more frequently than LAMB to treat neonatal candidiasis, despite the lack of PK data in neonates. [16, 17] The most commonly used markers of efficacy among the studies reviewed include time to infection eradication and mortality associated with candidiasis. As reported in Table 1 , while dosing was similar, many studies had variable durations of therapy and looked at combination therapy with flucytosine or fluconazole, which may have influenced the reported efficacy of DAMB. [16] Based on retrospective studies published after 2001 comparing different lipid formulations to DAMB, DAMB was associated with a survival rate of over 75%, a reported time to eradication between 6 and 10 days of therapy, and a Candida-associated mortality rate ranging between 0 and 10%. [17] [18] [19] [20] [21] The only prospective randomized controlled trial evaluating the efficacy of DAMB demonstrated no significant difference in mortality when compared to fluconazole. [22] In newborns, CNS involvement has been estimated to occur in 25% of candidiasis cases. [23] Additionally, CSF samples may be unreliable as infection markers, such as glucose, white blood cells and protein, may not be captured. [24] Imaging studies may lack sensitivity to optimally detect CNS involvement and therefore CNS involvement should be assumed in neonatal candidiasis. [25] In a 10-year retrospective review looking at Candida meningitis, DAMB was associated with a 26% mortality rate, which was reduced from a previous mortality rate of 60% before DAMB came to market in the 1950s. [23, 26] Due to this demonstrated reduction in mortality, DAMB is a preferred therapeutic option to treat Candida meningitis.
Additionally, due to the lower concentration of LAMB in the kidneys, DAMB remains the preferred therapeutic option for fungal infections with renal involvement. [5] These differences in renal penetration and documented efficacy in the setting of CNS involvement remain the primary advantages of DAMB over LAMB. Although duration of therapy may vary, a dose of 1 mg/kg intravenous once daily for DAMB seems appropriate, pending further studies. [5] Liposomal amphotericin B
Although there are no randomized controlled trials evaluating LAMB in neonates, this lipid formulation has been utilized as an alternative to DAMB for neonatal candidiasis when renal involvement can be ruled out. [16, 17] Limited data on use in neonates exist, including retrospective, small studies (see Table 2 ). Complete eradication rates and mortality rates were similar when compared to DAMB among the studies included in this review (see Table 3 ). Mortality ranged from 0 to 27%. [17] [18] [19] [20] [21] Scarcella et al. reported a 27% mortality rate in 44 subjects, which authors commented may be due to delayed diagnosis along with insufficient dosing, rather than a lack of medication efficacy. In this study, LAMB doses ranged between 1 and 5 mg/kg per day. This study also reported eradication of infection with LAMB monotherapy in 5 of 6 fungal meningitis cases, which may suggest adequate CNS coverage. Time to eradication ranged between 4 and 9 days of therapy. JusterReicher et al. [18] reported a trend towards faster time to fungal eradication in infants with birthweights ranging between 1000 g and 1430 g, in infants without prior DAMB exposure, and in infants with a faster dose titration (<96 h). In this study, LAMB doses ranged between 5 and 7 mg/kg per day. Linder et al. [20] reported a trend towards higher rates of eradication in the LAMB group when compared to the DAMB group (83.3% vs 67.7%, respectively). The LAMB dose used for all infants was 5 mg/kg per day. While this finding did not meet statistical significance, significant differences in baseline characteristics existed including a lower gestational age and birthweight, less antenatal steroid use and increased ventilation duration in the LAMB group. These baseline differences highlight the potential efficacy of LAMB in these sicker newborns, who had similar outcomes.
Moreover, these studies underline the dosing variability in LAMB, which suggest decreased efficacy when inadequate cumulative dosing regimens are used. A recent retrospective cohort study of 730 infants with neonatal candidiasis found a significantly higher mortality rate associated with all liposomal formulations when compared to DAMB (29% vs 18%, respectively; P = 0.01). [27] As seen in previous studies, this mortality difference may be associated with a difference in baseline illness. However, the exact cause of death, dosing of each agent and baseline characteristics including underlying illness were not reported. [27] Due to conflicting findings, randomized controlled trials of LAMB are needed to verify the efficacy of this formulation, including PK studies evaluating CSF levels to confirm adequate CNS penetration for use in neonatal meningitis.
Safety Conventional amphotericin B deoxycholate
Adverse effects related to the use of DAMB are well-documented. While the incidence in neonates may be less frequent due to faster clearance, electrolyte imbalances, nephrotoxicity and hepatotoxicity have been reported in varying rates (see Table 4 ). Renal adverse effects range from polyuria to renal failure and are hypothesized to be caused by enhancement of tubuloglomerular feedback, afferent arteriolar vasoconstriction and resultant tubular acidosis. [28] The definition of nephrotoxicity varied between studies, ranging from a serum creatinine >1 to >1.5 mg/dl, [17, 23] or nephrotoxicity was not reported at all. A retrospective study of 92 infants given DAMB showed a rate of nephrotoxicity of 17%. [29] No significant differences in baseline characteristics, cumulative dosing or duration of therapy existed among the infants evaluated. [29] Data are lacking regarding alterable risk factors of nephrotoxicity with DAMB use. Despite this adverse effect frequently being transient and reversible, DAMB may be used with strict monitoring parameters and therapy may be switched to LAMB if signs of toxicity develop. [9] Sodium loading has been shown to reduce the incidence of nephrotoxicity in newborns, and has now become common practice although the mechanism is not well-understood. Sodium supplementation above 4 mEq/kg per day may alter membrane permeability and reduce the amphotericininduced vasoconstriction of the afferent arteriole. [19, 30] Monitoring plasma drug levels or the total cumulative dose have not demonstrated reliable predictability of toxicity, leaving clinicians to individualize limits of cumulative exposure and duration of therapy while carefully monitoring renal function and electrolytes. Infusion-related reactions including rigors, fever, hypertension/hypotension, hypoxia and nausea/vomiting have also been well-documented with DAMB. [12] Liposomal amphotericin B Liposomal formulations were developed to minimize the toxicities associated with DAMB. [12] As previously mentioned, the molecular size and mechanism of targeted delivery is thought to be responsible for the reduced incidence of adverse effects of this agent. Although renal side effects are decreased compared to DAMB, transient rises in BUN and SCr, transient hypokalemia and hepatotoxicity are seen with LAMB therapy (see Table 5 ). [17] [18] [19] [20] [21] 31, 32 Incidence of hypokalemia ranges between 0 and 36%, rises in SCr and BUN between 6.2 and 21%, [17, 20] and hepatotoxicity, although not consistently reported, between 0 and 25%. [16, 21, 31, 32] Additionally, in a prospective analysis, high-dose regimens of 5-7 mg/kg per day as compared to the typical regimens of 1-5 mg/kg per day were not associated with increased incidence of adverse effects, including changes in BUN, SCr, serum potassium, bilirubin or hepatic transaminases. However, these findings were not statistically significant. [32] Of note, eight infants failed the conventional formulation or developed renal toxicity and were converted to LAMB. [32] A decrease in adverse effects is noted after conversion from DAMB to LAMB in multiple studies; however, the contribution to ongoing adverse effects cannot be known due to a lack of a washout period in these studies. [20, 21, 27] A statistically significant decrease in the incidence of hepatotoxicity (P = 0.014) and nephrotoxicity (P = 0.029) was shown in a prospective historical-control study in the LAMB group as compared to the DAMB group. [21] No change in oliguria, transient hypokalemia and thrombocytopenia was present. Additionally, LAMB is only rarely associated with infusion reactions in neonates, but slowing the infusion rate is still recommended. Based on limited data, LAMB appears to be a safe alternative to DAMB and may be associated with a lower incidence of adverse effects (Table 6 ).
Discussion
Available data on the use of conventional vs liposomal amphotericin B in neonatal candidiasis are limited by their small, non-controlled, retrospective nature and do not report on pertinent comorbidities. While advantages of LAMB may exist, including reduced hepatic and renal adverse effect potential, concerns may exist regarding renal and CNS penetration as well as mortality rates. Despite a shorter duration of therapy at a higher daily dose, LAMB was associated with a better side effect profile vs DAMB in most studies. [17] [18] [19] [20] [21] 31, 32] The tolerability of higher doses of LAMB holds promise when considering the concentrationdependent mechanism of this medication. As reported by Juster-Reicher et al., [32] higher dose regimens and faster dose titrations of LAMB were associated with more rapid fungal eradication. Although these results are limited due to a small study size, the lack of additional adverse effects associated with the increased dose regimen is intriguing. Moreover, most studies reviewed in this evaluation used typical dosing of LAMB (1-5 mg/kg per day) and displayed similar efficacy to the typical dosing of DAMB (1 mg/kg per day). [5] Limited quality data exist comparing the efficacy and safety of DAMB vs LAMB. One prospective multicentre, historical-control study of 46 VLBW infants given DAMB or LAMB observed a statistically significant shorter duration of therapy (P = 0.004), a lower incidence of hepatotoxicity (P = 0.014) and a lower incidence of nephrotoxicity (P = 0.029) in the LAMB group. [21] Rates of fungal eradication and mortality were similar between groups, as were potassium levels, oliguria rates and platelet counts.
Liposomal amphotericin B appears to be an efficacious alternative to conventional amphotericin B deoxycholate for neonatal candidiasis. However, the lack of data confirming adequate CNS penetration, as well as the known lack of renal penetration, limits the usefulness of LAMB as a first-line agent. Based on the available literature, LAMB's place in therapy may be as an alternative antifungal agent to DAMB in the setting of nephrotoxicity, hepatotoxicity or fluconazole-resistance, as long as CNS and renal involvement can be ruled out.
Conclusion
Liposomal amphotericin B appears to be an efficacious alternative to DAMB for NC. While cases of successful eradication of fungal meningitis have been reported, more studies are needed to verify adequate CNS penetration. [14, 33] Inadequate renal penetration may limit LAMB use for disseminated NC unless renal involvement can be ruled out. Based on current data, LAMB carries a lower adverse effect risk as compared to DAMB, which may be due to a more targeted delivery of the medication to the site of infection. Additionally, higher doses may potentially be used safely with this formulation allowing the ability to harness the medications concentration-dependent mechanism of activity. Despite these potential benefits of this formulation of amphotericin B, randomized controlled trials are needed to verify the safety and efficacy of the use of LAMB in NC. 
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